Portal de Periódicos da CAPES

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

2022; Elsevier BV; Volume: 399; Issue: 10337 Linguagem: Inglês

10.1016/s0140-6736(22)00538-4

1474-547X

Sinéad Delany‐Moretlwe, James P. Hughes, Peter Bock, Samuel Gurrion Ouma, Portia Hunidzarira, Dishiki Kalonji, Noel Kayange, Joseph Makhema, Patricia Mandima, Carrie Mathew, Elizabeth Spooner, Juliet Mpendo, Pamela Mukwekwerere, Nyaradzo Mgodi, Patricia Nahirya Ntege, Gonasagrie Nair, Clemensia Nakabiito, Harriet Nuwagaba‐Biribonwoha, Ravindre Panchia, Nishanta Singh, Bekezela Siziba, Jennifer Farrior, Scott Rose, Peter L. Anderson, Susan H. Eshleman, Mark A. Marzinke, Craig W. Hendrix, Stephanie Beigel-Orme, Sybil Hosek, Elizabeth E. Tolley, Nirupama Sista, Adeola Adeyeye, James F. Rooney, Alex R. Rinehart, William Spreen, Kimberly Y. Smith, Brett Hanscom, Myron S. Cohen, Mina C. Hosseinipour,

HIV Research and Treatment

Oral pre-exposure prophylaxis has been introduced in more than 70 countries, including many in sub-Saharan Africa, but women experience considerable barriers to daily pill-taking, such as stigma, judgement, and the fear of violence. Safe and effective long-acting agents for HIV prevention are needed for women. We aimed to evaluate the safety and efficacy of injectable cabotegravir compared with daily oral tenofovir diphosphate plus emtricitabine (TDF-FTC) for HIV prevention in HIV-uninfected women.